Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects
DOI:
https://doi.org/10.5489/cuaj.67Abstract
Sunitinib, a new vascular endothelial growth factor receptor inhibitor, has demonstrated high activity in renal cell carcinoma (RCC) and is now widelyused for patients with metastatic disease. Although generally well tolerated andassociated with a low incidence of common toxicity criteria grade 3 or 4 toxicities, sunitinib exhibits a distinct pattern of novel side effects that require monitoring and management. This article summarizes the most important side effects and proposes recommendations for their monitoring, prevention and treatment,based on the existing literature and on suggestions made by an expert groupof Canadian oncologists. Fatigue, diarrhea, anorexia, oral changes, skin toxicityand hypertension seem to be the most clinically relevant toxicities of sunitinib. Fatigue may be partly related to the development of hypothyroidismduring sunitinib therapy for which patients should be observed and, if necessary, treated. Hypertension can be treated with standard antihypertensivetherapy and rarely requires treatment discontinuation. Neutropenia and thrombocytopenia usually do not require intervention, in particular no episodes ofneutropenic fever have been reported to date. A decrease in left ventricula rejection fraction is a rare, but potentially life-threatening side effect. Becauseof its metabolism by cytochrome P450 3A4 a number of drugs can potentiallyinteract with sunitinib. Clinical response and toxicity should be carefullyobserved when sunitinib is combined with either a cytochrome P450 3A4 induceror inhibitor and doses adjusted as necessary. Knowledge about side effects, as well as the proactive assessment and consistent management of sunitinib related side effects, is critical to ensure optimal benefit from sunitinib treatment.Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.